Zobrazeno 1 - 10
of 274
pro vyhledávání: ''
Publikováno v:
Journal of Human Genetics
Breast cancer is a heterogeneous disease that develops through a multistep process via the accumulation of genetic/epigenetic alterations in various cancer-related genes. Current treatment options for breast cancer patients include surgery, radiother
Autor:
Ring, A., Battisti, N.M.L., Reed, M.W.R., Herbert, E., Morgan, J.L., Bradburn, M., Walters, S.J., Collins, K.A., Ward, S.E., Holmes, G.R., Burton, Maria, Lifford, K., Edwards, A., Robinson, T.G., Martin, C., Chater, T., Pemberton, K.J., Brennan, A., Cheung, K.L., Todd, A., Audisio, R.A., Wright, J., Simcock, R., Green, T., Revell, D., Gath, J., Horgan, K., Holcombe, C., Winter, M.C., Naik, J., Parmeshwar, R., Gosney, M.A., Hatton, M.Q., Thompson, A.M., Wyld, L., Collins, K., Ward, S., Holmes, G., Morgan, J., Walters, S., Burton, M., Brain, K., Robinson, T., Pemberton, K., Shrestha, A., Nettleship, A., Richards, P., Harder, H., Audisio, R., Murray, C., Thomson, A.M., Gosney, M., Hatton, M., Armitage, F., Patnick, J., Revill, D., Winter, M.
Publikováno v:
British Journal of Cancer
Background Chemotherapy improves outcomes for high risk early breast cancer (EBC) patients but is infrequently offered to older individuals. This study determined if there are fit older patients with high-risk disease who may benefit from chemotherap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8ed056944ecd27827ab3bd963813fe40
http://sro.sussex.ac.uk/id/eprint/101218/1/s41416-021-01388-9.pdf
http://sro.sussex.ac.uk/id/eprint/101218/1/s41416-021-01388-9.pdf
Autor:
James L. Thorne, Melina C. Teske, Robyn V. Broad, Andrew M. Hanby, Laura M. Wastall, Stacey J. Jones, Thomas A. Hughes
Publikováno v:
British Journal of Cancer
Background Triple negative breast cancers (TNBC) have poor prognoses despite aggressive treatment with cytotoxic chemotherapy. Cancer-associated fibroblasts (CAFs) are prominent in tumour stroma. Our hypothesis was that CAFs modulate chemotherapy sen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::027115557c95f3f47f1ecb119dec9f3d
Autor:
Sylwia Kopijasz, Corran Roberts, Victoria Y Strauss, Shibani Nicum, Andrew R Clamp, Marcia Hall, Richard D. Kennedy, Ana Montes, Charlie Gourley, Jacinta Abraham, Michael R.L. Stratford, Susana Banerjee, Lisa K. Folkes
Publikováno v:
Roberts, C, Strauss, V Y, Kopijasz, S, Gourley, C, Hall, M, Montes, A, Abraham, J, Clamp, A, Kennedy, R, Banerjee, S, Folkes, L K, Stratford, M & Nicum, S 2020, ' Results of a phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumours ', British Journal of Cancer, vol. 122, no. 4, pp. 483-490 . https://doi.org/10.1038/s41416-019-0674-4, https://doi.org/10.1038/s41416-019-0674-4
Roberts, C, Strauss, V Y, Kopijasz, S, Gourley, C, Hall, M, Montes, A, Abraham, J, Clamp, A, Kennedy, R, Banerjee, S, Folkes, L K, Stratford, M & Nicum, S 2020, ' Results of a phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumours ', British Journal of Cancer, vol. 122, no. 4, pp. 483-490 . https://doi.org/10.1038/s41416-019-0674-4
British Journal of Cancer
Roberts, C, Strauss, V Y, Kopijasz, S, Gourley, C, Hall, M, Montes, A, Abraham, J, Clamp, A, Kennedy, R, Banerjee, S, Folkes, L K, Stratford, M & Nicum, S 2020, ' Results of a phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumours ', British Journal of Cancer, vol. 122, no. 4, pp. 483-490 . https://doi.org/10.1038/s41416-019-0674-4
British Journal of Cancer
BackgroundTumour cells with BRCA1/2 gene mutations demonstrate increased sensitivity to platinum and poly (ADP-ribose) polymerase (PARP) inhibitors. 6-mercaptopurine (6MP) was found to selectively kill BRCA-defective cells in a xenograft model as eff
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f2b494bdec4a88dbce8776a6e9b65b9c
https://doi.org/10.1038/s41416-019-0674-4
https://doi.org/10.1038/s41416-019-0674-4
Autor:
Lusine Tumyan, Daniel Schmolze, Joanne E. Mortimer, Daniel Abler, David A. Hormuth, Angela M. Jarrett, Vikram Adhikarla, Prativa Sahoo, Thomas E. Yankeelov, Russell C. Rockne
Publikováno v:
Scientific Reports
Scientific Reports, Vol 10, Iss 1, Pp 1-14 (2020)
Jarrett, Angela M.; Hormuth, David A.; Adhikarla, Vikram; Sahoo, Prativa; Abler, Daniel; Tumyan, Lusine; Schmolze, Daniel; Mortimer, Joanne; Rockne, Russell C.; Yankeelov, Thomas E. (2020). Towards integration of 64Cu-DOTA-trastuzumab PET-CT and MRI with mathematical modeling to predict response to neoadjuvant therapy in HER2 + breast cancer. Scientific reports, 10(1), p. 20518. Springer Nature 10.1038/s41598-020-77397-0
Scientific Reports, Vol 10, Iss 1, Pp 1-14 (2020)
Jarrett, Angela M.; Hormuth, David A.; Adhikarla, Vikram; Sahoo, Prativa; Abler, Daniel; Tumyan, Lusine; Schmolze, Daniel; Mortimer, Joanne; Rockne, Russell C.; Yankeelov, Thomas E. (2020). Towards integration of 64Cu-DOTA-trastuzumab PET-CT and MRI with mathematical modeling to predict response to neoadjuvant therapy in HER2 + breast cancer. Scientific reports, 10(1), p. 20518. Springer Nature 10.1038/s41598-020-77397-0
While targeted therapies exist for human epidermal growth factor receptor 2 positive (HER2 +) breast cancer, HER2 + patients do not always respond to therapy. We present the results of utilizing a biophysical mathematical model to predict tumor respo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::34d692269c2e8a618712ec30483dae71
Autor:
Miguel Gil-Gil, José A. García-Sáenz, E Dalmau Portulas, Elena García-Martínez, Nuria Ribelles, A. Santaballa Bertran, E. Martínez de Dueñas, I Alvarez-Lopez, Susana Bezares
Publikováno v:
Dipòsit Digital de la UB
Universidad de Barcelona
Clinical & Translational Oncology
Universidad de Barcelona
Clinical & Translational Oncology
PurposeHormone receptor (HR)-positive, Human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC) requires a therapeutic approach that takes into account multiple factors, with treatment being based on anti-estrogen hormo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b63a263cb82f360402dddafab187eefb
http://hdl.handle.net/2445/174389
http://hdl.handle.net/2445/174389
Autor:
Hisashi Motomura, Wataru Goto, Shinichiro Kashiwagi, Yuka Asano, Shuhei Tomita, Koji Takada, Masahiko Ohsawa, Katsuyuki Takahashi, Kosei Hirakawa, Masaichi Ohira, Tsutomu Takashima, Takaharu Hatano
Publikováno v:
British Journal of Cancer
Background Immune responses in a tumour microenvironment can be evaluated by analysing tumour-infiltrating lymphocyte (TIL) density; this has been verified in the clinical setting. Although there are many reports on TIL density in primary tumours, li
Publikováno v:
Digital.CSIC. Repositorio Institucional del CSIC
instname
instname
[Background] Current therapeutic strategies that are used to combat breast cancer vary widely and largely depend on its clinicopathological features, including tumor subtype, size, stage, lymph node involvement, the presence of hormone receptors and/
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff6f37dcbb5ea82449e8289a41c8b7ba
http://hdl.handle.net/10261/201673
http://hdl.handle.net/10261/201673
Autor:
Judy Garber, Clara Li, Kevin S. Hughes, Suzanne B. Coopey, Francisco Acevedo, Amy S. Colwell, Danielle Braun, Regina Barzilay, Adam Yala, Tari A. King, Barbara L. Smith, Anthony J. Guidi, Curtis L. Cetrulo, Rong Tang, V. Diego Armengol, Zhengyi Deng
Publikováno v:
Other repository
© 2018, Springer Science+Business Media, LLC, part of Springer Nature. Purpose: Mammoplasty removes random samples of breast tissue from asymptomatic women providing a unique method for evaluating background prevalence of breast pathology in normal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18e84cacd853968a680255161596c752
https://hdl.handle.net/1721.1/134753
https://hdl.handle.net/1721.1/134753
Autor:
Zsuzsanna Varga, Thomas Ruhstaller, Ulrike Perriard, Dirk Klingbiel, Tilman T. Rau, Jean-Christophe Tille, Beat Thuerlimann, Hanne Hawle, Qiyu Li, Wolfram Jochum
Publikováno v:
Varga, Zsuzsanna; Li, Qiyu; Jochum, Wolfram; Perriard, Ulrike; Rau, Tilman; Tille, Jean-Christoph; Hawle, Hanne; Klingbiel, Dirk; Thuerlimann, Beat; Ruhstaller, Thomas (2019). Ki-67 assessment in early breast cancer: SAKK28/12 validation study on the IBCSG VIII and IBCSG IX cohort. Scientific reports, 9(1), p. 13534. Springer Nature 10.1038/s41598-019-49638-4
Scientific Reports, Vol 9, Iss 1, Pp 1-11 (2019)
Scientific Reports, Vol. 9, No 1 (2019) P. 13534
Scientific Reports
Scientific Reports, Vol 9, Iss 1, Pp 1-11 (2019)
Scientific Reports, Vol. 9, No 1 (2019) P. 13534
Scientific Reports
The assessment of Ki-67 in early-stage breast cancer has become an important diagnostic tool in planning adjuvant therapy, particularly for the administration of additional chemotherapy to hormone-responsive patients. An accurate determination of the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::509ed0eb6c511bb431eb561f8c240921